title: Molecularly targeted therapies for acute myeloid leukemia.
abstract: The past 15 years have seen major leaps in our understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia (AML). Clinical trials of agents against specific mutant proteins, such as FLT3-internal tandem duplications (ITDs) and isocitrate dehydrogenase mutations (IDHs) are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets.
authors.affiliation: Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Eytan M
authors.initials: EM
authors.lastname: Stein
mesh_terms: D000814:Aniline Compounds / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D052160:Benzothiazoles / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D044127:Epigenesis, Genetic; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy; D009154:Mutation; D010671:Phenylurea Compounds / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D011719:Pyrazines / Q000627:therapeutic use; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D052160:Benzothiazoles; D007521:Isocitrate Dehydrogenase; D010671:Phenylurea Compounds; D010880:Piperidines; D019253:Proto-Oncogene Proteins c-bcl-2; D011719:Pyrazines; D051941:fms-Like Tyrosine Kinase 3; C000609080:gilteritinib; C544967:quizartinib; C538784:IDH2 protein, human; C543588:IDH1 protein, human; C497970:FLT3 protein, human; C577197:crenolanib